February 2021 - Page 4 of 5 - BioMedWire (BMW)

WednesdayFeb 10, 2021 2:14 pm

Predictive Oncology Inc. (NASDAQ: POAI) Enters into Definitive Agreements for Direct Offering Totaling Estimated $3 Million

Definitive agreements with institutional, accredited investors call for issuance and sale of more than 3.5 million shares of common stock POAI currently focused on applying AI to develop personalized medical treatments, novel lab media and improved vaccines One of POAI’s highest priorities is building multi-omic predictive models of tumor drug response and outcome Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, has entered into definitive agreements with several investors for the sale of common stock (https://ibn.fm/YcBGM). The agreements with several institutional and accredited investors call for the issuance and sale…

TuesdayFeb 09, 2021 2:15 pm

Biological Sensors May Provide Physicians with Insights on Whether Treatments Are Effective

Patients suffering from potentially fatal diseases, such as cancer, may often undergo weeklong gaps that are discomforting when their courses of treatment begins. Doctors use this period to learn whether a patient’s treatment is working, and while it’s the standard way of doing things, the approach prevents health-care professionals from tracking the disease’s progression in real time. Enter Glympse Bio, a start-up that originated from Sangeeta Bhatia’s laboratory. Sangeeta Bhatia is the Marble Center for Cancer Nanomedicine director as well as an MIT Professor of Electrical Engineering and Computer Science. The start-up has developed small synthetic biosensors that can be…

MondayFeb 08, 2021 2:33 pm

United Medical Equipment Business Solutions Network Inc. Offers Rapid COVID-19 Test Designed to Identify Infection

FDA has authorized 225-plus diagnostic tests for COVID-19 since pandemic began CareStart(TM) COVID-19 antigen test received FDA authorization in July 2020 UME carries CareStart antigen kit, a powerful component of COVID-19 screening process Since the beginning of the COVID-19 pandemic, the U.S. Food and Drug Administration (“FDA”) has authorized more than 225 diagnostic tests for COVID-19 in an effort to provide growing resources to combat the disease. United Medical Equipment Business Solutions Network (“UME”), a company committed to offering a comprehensive line set of COVID-19 products, recently added one of those tests — the CareStart(TM) COVID-19 rapid antigen kit —…

MondayFeb 08, 2021 2:26 pm

RYAH Group Inc. Well Positioned as Data Continues to Shape Future of Medical Research

Recent article finds that data remains one of main drivers of medical research in 2021. New technologies employing AI powered by big data provide new solutions for tackling health problems, expand possibilities of clinical research RYAH combines power of devices combined with data to impact future of medical research to advance treatment of various medical conditions A recent Becker’s Hospital Review article cites 10 emerging trends in health IT that will shape this field in 2021, reporting that big data management is becoming a need as the use of artificial intelligence (“AI”) and machine learning in healthcare continues to blossom (https://ibn.fm/bMPIY).…

MondayFeb 08, 2021 1:17 pm

2021 Strategic Plan Showcases API Potential of XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT)

XPhyto Therapeutics Corp. is a life sciences technology accelerator involved in the development of new pharmaceuticals, diagnostic products and psychedelic investments XPhyto is preparing a series of clinical pilot studies for four drug candidates this year that could help in treating Parkinson’s disease, epilepsy, anorexia and other neurological conditions The company has developed a rapid and highly portable PCR test kit it expects to commercialize this year to provide point-of-care diagnostics, designed for satellite labs to quickly screen for the COVID-19 virus Wholly owned subsidiary Vektor, a German drug maker and researcher, plans to build a new commercial drug manufacturing…

MondayFeb 08, 2021 1:00 pm

New Discovery May Revolutionize the Treatment of Diabetes

A recent study conducted by researchers from the German Center for Diabetes Research, the Technical University of Munich and the Helmholtz Zentrum München has found a new and druggable insulin inhibitory receptor called inceptor. The study is a remarkable discovery for research on diabetes as the scientific community celebrates 50 years since the discovery of the insulin receptor and 100 years since the discovery of insulin. The researchers found that blocking inceptor function led to increased sensitization of the insulin signaling pathway. This, they said, may allow the regeneration and protection of beta cells for diabetes remission. Diabetes mellitus is…

MondayFeb 08, 2021 12:11 pm

Predictive Oncology Inc. (NASDAQ: POAI) Stands to Benefit from Explosive Growth of Precision Medicine

Precision medicine in oncology allows for clinicians to develop personalized cancer treatment plans using individual characteristics of each patient Doctors use insights drawn from laboratory-grown cancer cells, patients’ DNA to individualize cancer treatment Predictive Oncology has been forerunner in its field, both through Helomics division’s smart tumor profiling platform as well as TumorGenesis subsidiary, which creates the tools used in ovarian cancer research TumorGenesis has begun to commercialize intellectual property, having received first order for unique ovarian cancer cell culture media in June 2020 In the summer of 2018, 49-year-old Star Dolbier arrived at the University of Maryland Greenebaum Cancer…

FridayFeb 05, 2021 1:43 pm

Imagin Medical Inc.’s (CSE: IME) (OTCQB: IMEXF) Proprietary System Could Help Reduce Bladder Cancer Recurrence

The current standard for bladder cancer visualization, white light, is over three decades old and used in 95% of the bladder cancer surgeries The recurrence rate of bladder cancer is more than 50% due to the inability to see clear margins in the white light surgical standard for visualization Imagin Medical Inc.’s proprietary i/Blue(TM) System changes the way that surgeons visualize bladder cancer with side-by-side imaging of white and blue light pictures on one screen Blue light procedures are capable of reducing recurrence rates by 12-43% depending on the type, stage, and grade of bladder cancer The global bladder cancer…

FridayFeb 05, 2021 1:31 pm

Brain Scientific Inc. (BRSF) Helps Identify Decision Triggers in Super Bowl Ads and COVID-19 Ads

Using BRSF's EEG products, Marketing Brainology was able to identify the most effective method for dispensing COVID-19 messaging Collected invaluable data for the current pandemic as well as how to navigate the future Brain Scientific (OTCQB: BRSF) is focused on developing innovative and proprietary medical devices and software. As the company works to modernize brain diagnostics through cutting-edge tech, it has also collaborated with Marketing Brainology, a neuromarketing firm that uses neuroscience to understand consumer behavior. In 2019, Marketing Brainology conducted a test to measure Super Bowl advertisements' impact using the NeuroCap, disposable EEG headset and NeuroEEG, a 16-channel EEG…

FridayFeb 05, 2021 11:30 am

Study Finds Post-Op Pain-Management Medication Doesn’t Have to Include Opioids

A team of researchers from Michigan Medicine-University of Michigan conducted a study on post-op pain management that involved 620 patients who had undergone operations in various hospitals across the state. For the study, patients had their use of painkillers tracked and then participated in surveys in the months following their surgeries. In the study, which was reported in “JAMA Surgery,” researchers noted that, prior to surgery, half of the patients were counselled on alternative treatments for pain management that did not involve opioids. A third of the patients in this particular group were not prescribed any opioids post-surgery while the…

News and publishing service for medical and biotechnology related companies

Contact us: 415.949.5050

Month: February 2021

Predictive Oncology Inc. (NASDAQ: POAI) Enters into Definitive Agreements for Direct Offering Totaling Estimated $3 Million

Biological Sensors May Provide Physicians with Insights on Whether Treatments Are Effective

United Medical Equipment Business Solutions Network Inc. Offers Rapid COVID-19 Test Designed to Identify Infection

RYAH Group Inc. Well Positioned as Data Continues to Shape Future of Medical Research

2021 Strategic Plan Showcases API Potential of XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT)

New Discovery May Revolutionize the Treatment of Diabetes

Predictive Oncology Inc. (NASDAQ: POAI) Stands to Benefit from Explosive Growth of Precision Medicine

Imagin Medical Inc.’s (CSE: IME) (OTCQB: IMEXF) Proprietary System Could Help Reduce Bladder Cancer Recurrence

Brain Scientific Inc. (BRSF) Helps Identify Decision Triggers in Super Bowl Ads and COVID-19 Ads

Study Finds Post-Op Pain-Management Medication Doesn’t Have to Include Opioids

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search